Published in Mol Cell on October 10, 2008
Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol (2011) 2.96
mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66
Where is mTOR and what is it doing there? J Cell Biol (2013) 1.91
Suppression of RhoG activity is mediated by a syndecan 4-synectin-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation pathway. J Cell Biol (2009) 1.36
Ceramide and ceramide 1-phosphate in health and disease. Lipids Health Dis (2010) 1.24
Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons. Neuron (2011) 1.21
Early endosomal antigen 1 (EEA1) is an obligate scaffold for angiotensin II-induced, PKC-alpha-dependent Akt activation in endosomes. J Biol Chem (2010) 1.01
Syndecan-4 signaling at a glance. J Cell Sci (2013) 1.01
Pregnancy-specific glycoprotein 1 induces endothelial tubulogenesis through interaction with cell surface proteoglycans. J Biol Chem (2010) 0.98
Mammalian TOR signaling to the AGC kinases. Crit Rev Biochem Mol Biol (2011) 0.97
Rapid mitogenic regulation of the mTORC1 inhibitor, DEPTOR, by phosphatidic acid. Mol Cell (2015) 0.95
Angiopoietin-2 secretion by endothelial cell exosomes: regulation by the phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS) and syndecan-4/syntenin pathways. J Biol Chem (2013) 0.95
Syndecan 4 regulates FGFR1 signaling in endothelial cells by directing macropinocytosis. Sci Signal (2012) 0.94
Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes. J Biol Chem (2011) 0.93
Dynamic Visualization of mTORC1 Activity in Living Cells. Cell Rep (2015) 0.88
Glucose activates TORC2-Gad8 protein via positive regulation of the cAMP/cAMP-dependent protein kinase A (PKA) pathway and negative regulation of the Pmk1 protein-mitogen-activated protein kinase pathway. J Biol Chem (2014) 0.86
Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome. Nat Med (2017) 0.86
Localization of mTORC2 activity inside cells. J Cell Biol (2017) 0.86
Syndecan-4 is a major syndecan in primary human endothelial cells in vitro, modulated by inflammatory stimuli and involved in wound healing. J Histochem Cytochem (2015) 0.85
The syndecan-4/protein kinase Cα pathway mediates prostaglandin E2-induced extracellular regulated kinase (ERK) activation in endothelial cells and angiogenesis in vivo. J Biol Chem (2013) 0.85
Structural basis for the association of the redox-sensitive target of rapamycin FATC domain with membrane-mimetic micelles. J Biol Chem (2009) 0.84
HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells. Am J Physiol Cell Physiol (2012) 0.84
Syndecan 4 regulation of PDK1-dependent Akt activation. Cell Signal (2012) 0.81
The role of the Niemann-Pick disease, type C1 protein in adipocyte insulin action. PLoS One (2014) 0.80
A shift of the TOR adaptor from Rictor towards Raptor by semaphorin in C. elegans. Nat Commun (2011) 0.79
Nonautonomous regulation of neuronal migration by insulin signaling, DAF-16/FOXO, and PAK-1. Cell Rep (2013) 0.78
Auxiliary and autonomous proteoglycan signaling networks. Methods Enzymol (2010) 0.78
Gab1 is essential for membrane translocation, activity and integrity of mTORCs after EGF stimulation in urothelial cell carcinoma. Oncotarget (2015) 0.78
The proteoglycan syndecan 4 regulates transient receptor potential canonical 6 channels via RhoA/Rho-associated protein kinase signaling. Arterioscler Thromb Vasc Biol (2011) 0.78
Syndecan-1 regulates vascular smooth muscle cell phenotype. PLoS One (2014) 0.78
Diacylglycerol kinase-ζ regulates mTORC1 and lipogenic metabolism in cancer cells through SREBP-1. Oncogenesis (2015) 0.77
Syndecan 4 signaling is required for exercise-induced cardiac hypertrophy. Mol Med (2016) 0.77
Regulation of the Target of Rapamycin and Other Phosphatidylinositol 3-Kinase-Related Kinases by Membrane Targeting. Membranes (Basel) (2015) 0.76
Knockdown expression of Syndecan in the fat body impacts nutrient metabolism and the organismal response to environmental stresses in Drosophila melanogaster. Biochem Biophys Res Commun (2016) 0.75
Vascular smooth muscle cell glycocalyx mediates shear stress-induced contractile responses via a Rho kinase (ROCK)-myosin light chain phosphatase (MLCP) pathway. Sci Rep (2017) 0.75
mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. Alzheimers Dement (2016) 0.75
Phospholipase D1 deficiency in mice causes nonalcoholic fatty liver disease via an autophagy defect. Sci Rep (2016) 0.75
Syndecan-4 modulates the proliferation of neural cells and the formation of CaP axons during zebrafish embryonic neurogenesis. Sci Rep (2016) 0.75
Positive feedback in cardioprotection: can more mechanism lead to translation? Circ Res (2014) 0.75
Gonadotropin releasing hormone activation of the mTORC2/Rictor complex regulates actin remodeling and ERK activity in LβT2 cells. Mol Cell Endocrinol (2016) 0.75
The mTOR-FAK mechanotransduction signaling axis for focal adhesion maturation and cell proliferation. Am J Transl Res (2017) 0.75
Killing two birds with one stone: dual blockade of integrin and FGF signaling through targeting syndecan-4 in postoperative capsular opacification. Cell Death Dis (2017) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev (2002) 8.31
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol (2004) 7.59
Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev (2003) 5.91
mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem (2005) 5.62
Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res (2002) 4.83
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J (2008) 4.79
The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res (1999) 4.66
Expanding mTOR signaling. Cell Res (2007) 4.01
Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest (2001) 2.78
The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem (2005) 2.44
Syndecans: new kids on the signaling block. Circ Res (2005) 2.43
Akt1 in endothelial cell and angiogenesis. Cell Cycle (2006) 2.22
Control of morphology, cytoskeleton and migration by syndecan-4. J Cell Sci (1999) 2.17
Protein kinase C-dependent mobilization of the alpha6beta4 integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells. J Cell Biol (1999) 1.98
Neutrophils from MMP-9- or neutrophil elastase-deficient mice show no defect in transendothelial migration under flow in vitro. J Leukoc Biol (2002) 1.62
Development of endothelial cell lines from embryonic stem cells: A tool for studying genetically manipulated endothelial cells in vitro. Arterioscler Thromb Vasc Biol (2000) 1.57
Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol (2002) 1.56
Clustering induces redistribution of syndecan-4 core protein into raft membrane domains. J Biol Chem (2002) 1.43
Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase C alpha (PKC alpha) increases focal adhesion localization of PKC alpha. J Biol Chem (2003) 1.36
Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal (2004) 1.29
PKCalpha activates eNOS and increases arterial blood flow in vivo. Circ Res (2005) 1.22
Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase Calpha. J Biol Chem (1998) 1.18
Protein kinase C-alpha overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal. Oncogene (1999) 1.10
Syndecan-4 regulates localization, activity and stability of protein kinase C-alpha. Biochem J (2004) 1.03
Syndecan-4-mediated signalling. Cell Signal (2001) 1.00
Effect of overexpression of constitutively active PKCalpha on rat lacrimal gland protein secretion. Invest Ophthalmol Vis Sci (2004) 0.94
Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. Am J Physiol Heart Circ Physiol (2003) 0.93
IgA Fc receptor (FcalphaR) cross-linking recruits tyrosine kinases, phosphoinositide kinases and serine/threonine kinases to glycolipid rafts. Biochem J (2002) 0.92
Modulation of microvascular signaling by heparan sulfate matrix: studies in syndecan-4 transgenic mice. Microvasc Res (2002) 0.83
Renal baroreceptor-stimulated renin in the eNOS knockout mouse. Am J Physiol Renal Physiol (2002) 0.83
Tissue-engineered lungs for in vivo implantation. Science (2010) 5.90
Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity. Circulation (2013) 2.95
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 2.82
Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature (2011) 2.47
Syndecans: new kids on the signaling block. Circ Res (2005) 2.43
Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell (2011) 2.42
VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell (2010) 2.37
ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell (2012) 2.14
Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation (2005) 2.13
The FGF system has a key role in regulating vascular integrity. J Clin Invest (2008) 2.09
Regulation of vascular smooth muscle cell differentiation. J Vasc Surg (2007) 1.92
A chemical and genetic approach to the mode of action of fumagillin. Chem Biol (2006) 1.91
Medical device development: from prototype to regulatory approval. Circulation (2004) 1.90
Selective regulation of arterial branching morphogenesis by synectin. Dev Cell (2006) 1.77
Branching morphogenesis. Circ Res (2008) 1.77
Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation (2004) 1.71
Modeling supravalvular aortic stenosis syndrome with human induced pluripotent stem cells. Circulation (2012) 1.69
FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep (2012) 1.63
Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol (2008) 1.56
FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest (2011) 1.56
The neuropilin 1 cytoplasmic domain is required for VEGF-A-dependent arteriogenesis. Dev Cell (2013) 1.54
Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest (2007) 1.49
Post-market approval surveillance: a call for a more integrated and comprehensive approach. Circulation (2004) 1.49
ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. J Clin Invest (2010) 1.45
VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol (2012) 1.44
Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol (2004) 1.43
Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ Res (2008) 1.43
Clustering induces redistribution of syndecan-4 core protein into raft membrane domains. J Biol Chem (2002) 1.43
Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J Biol Chem (2008) 1.38
Suppression of RhoG activity is mediated by a syndecan 4-synectin-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation pathway. J Cell Biol (2009) 1.36
Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci U S A (2003) 1.33
Syndecan-4 clustering induces cell migration in a PDZ-dependent manner. Circ Res (2006) 1.31
Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. J Cell Sci (2004) 1.30
Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal (2004) 1.29
Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J Cell Biol (2002) 1.26
Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. J Appl Physiol (1985) (2003) 1.25
The extracellular matrix and blood vessel formation: not just a scaffold. J Cell Mol Med (2007) 1.25
Endothelial ERK signaling controls lymphatic fate specification. J Clin Invest (2013) 1.24
PKCalpha activates eNOS and increases arterial blood flow in vivo. Circ Res (2005) 1.22
Non-canonical fibroblast growth factor signalling in angiogenesis. Cardiovasc Res (2007) 1.22
Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome. Development (2012) 1.21
Delayed arteriogenesis in hypercholesterolemic mice. Circulation (2005) 1.19
Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res (2008) 1.17
Transcriptional profiling in coronary artery disease: indications for novel markers of coronary collateralization. Circulation (2006) 1.17
Arteriogenesis: noninvasive quantification with multi-detector row CT angiography and three-dimensional volume rendering in rodents. Radiology (2006) 1.16
Expression of VEGF and angiopoietins-1 and -2 during ischemia-induced coronary angiogenesis. Am J Physiol Heart Circ Physiol (2003) 1.16
Phosphorylation of VE-cadherin controls endothelial phenotypes via p120-catenin coupling and Rac1 activation. Am J Physiol Heart Circ Physiol (2010) 1.15
Activation of Hedgehog signaling by the environmental toxicant arsenic may contribute to the etiology of arsenic-induced tumors. Cancer Res (2010) 1.15
Humoral and cellular factors responsible for coronary collateral formation. Am J Cardiol (2006) 1.14
High-resolution quantitative computed tomography demonstrating selective enhancement of medium-size collaterals by placental growth factor-1 in the mouse ischemic hindlimb. Circulation (2006) 1.13
Copper chelation represses the vascular response to injury. Proc Natl Acad Sci U S A (2003) 1.13
The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol (2006) 1.12
Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol (2009) 1.10
Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol (2012) 1.10
Micro computed tomography for vascular exploration. J Angiogenes Res (2010) 1.09
Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol (2005) 1.09
Cell communications in the heart. Circulation (2010) 1.09
VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med (2014) 1.08
Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol (2005) 1.08
The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque. Circ Res (2009) 1.07
Dll4-Notch signaling determines the formation of native arterial collateral networks and arterial function in mouse ischemia models. Development (2013) 1.07
Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest. Proc Natl Acad Sci U S A (2006) 1.07
Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry (2003) 1.07
Endothelial-to-mesenchymal transition drives atherosclerosis progression. J Clin Invest (2015) 1.06
Endothelial nuclear factor-κB-dependent regulation of arteriogenesis and branching. Circulation (2012) 1.06
Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med (2003) 1.06
Protein kinase C (PKC) delta regulates PKCalpha activity in a Syndecan-4-dependent manner. J Biol Chem (2002) 1.06
Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4. Arterioscler Thromb Vasc Biol (2011) 1.05
Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat (2006) 1.04
Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell (2013) 1.01
Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. Cardiovasc Res (2005) 1.01
Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. Int J Biochem Cell Biol (2008) 1.01
Syndecan-4 signaling at a glance. J Cell Sci (2013) 1.01
Endothelial cell-dependent regulation of arteriogenesis. Circ Res (2013) 1.00
Synectin/syndecan-4 regulate coronary arteriolar growth during development. Dev Dyn (2007) 1.00
The critical role of transmembrane prolines in human prostacyclin receptor activation. Mol Pharmacol (2002) 0.99
Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. J Lipid Res (2008) 0.99
NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J Clin Invest (2013) 0.99
Angiogenesis in the human heart: gene and cell therapy. Angiogenesis (2005) 0.97
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clin Cancer Res (2009) 0.96
Endothelial cell activation of the smooth muscle cell phosphoinositide 3-kinase/Akt pathway promotes differentiation. J Vasc Surg (2005) 0.96
Effects of cell grafting on coronary remodeling after myocardial infarction. J Am Heart Assoc (2013) 0.95
Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg (2002) 0.95